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Pentraxin 3 (PTX3) is a novel acute ‑phase 
reactant produced by various cells including 
monocytes/macrophages, neutrophils, vascular 
smooth muscle cells, fibroblasts, and endotheli‑
al cells. Importantly, PTX3 levels correlate with 
the risk of vascular events.1-3 PTX3 is synthe‑
sized locally at the inflammatory sites and may 
represent a marker of local inflammation at sites 
of vessel injury. PTX3 has additional regulato‑
ry functions, including effects on angiogenesis, 
INTRODUCTION Vascular calcifications are 
the most important risk factor in the pathogen‑
esis of cardiovascular diseases (CVDs) in patients 
with chronic kidney disease (CKD). In addition, 
the presence of endothelial dysfunction is asso‑
ciated with inflammation, which has repeated‑
ly been shown to enhance the risk for cardiovas‑
cular (CV) mortality both in renal and nonrenal 
populations.1
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ABSTRACT
INTRODUCTION Pentraxin 3 (PTX3) is involved in inflammatory response by recognizing pathogens and 
damaged tissues.
OBJECTIVES The aim of this study was to assess the relationship between PTX3 levels and all ‑cause 
and cardiovascular (CV) mortality in patients with chronic kidney disease (CKD) during 5 ‑year follow ‑up.
PATIENTS AND METHODS The study included 78 patients (51 on hemodialysis and 27 on predialysis). 
We measured the levels of PTX3, calcium, phosphate, intact parathyroid hormone, high‑sensitivity C‑
reactive protein (hs‑CRP), interleukin 6 (IL ‑6), fibroblast growth factor 23 (FGF ‑23), osteopontin (OPN), 
osteocalcin (OC), osteoprotegerin (OPG), fetuin A, tumor necrosis factor receptor 2 (TNFR2), transform‑
ing growth factor β1 (TGF ‑β1), hepatocyte growth factor (HGF), stromal cell ‑derived factor 1α (SDF ‑1α), 
and thrombomodulin (TM). In a subgroup of 45 patients, fragments of the radial artery obtained during 
creation of hemodialysis access were stained for calcifications. In 51 patients, ultrasonography was 
performed to assess common carotid artery intima–media thickness (CCA ‑IMT).
RESULTS The median serum concentrations of PTX3 were 1.43 ng/ml (interquartile range, 0.74–2.50). 
Higher concentrations of fibrinogen, hs ‑CRP, IL ‑6, TNFR2, TGF ‑β1, HGF, OPN, OPG, FGF ‑23, TM, and 
SDF ‑1α and lower albumin and uric acid levels were observed in patients with PTX3 above the median. 
During follow ‑up, 27 patients (35%) died, including 25 due to CV causes. In contrast to hs‑CRP levels, 
baseline PTX3 levels predicted CV mortality independently of classic CV risk factors. PTX3 levels also 
significantly predicted mortality after adjustment for age, baseline dialysis status, serum OPG and CRP 
levels, radial artery calcifications, and CCA ‑IMT.
CONCLUSIONS We postulate that PTX3 might be an early marker of CV mortality in patients with advanced 
CKD, yet before the increase in the levels of a specific marker for systemic inflammation such as hs ‑CRP.
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Department of Nephrology, University Hospital, 
Kraków, Poland, including 51 patients on mainte‑
nance HD and 27 patients on predialysis.
At baseline, 10 ‑year risk of death from CVD 
was calculated using the Polish version of the Sys‑
tematic Coronary Risk Evaluation (SCORE)12 
in accordance with the published guidelines.13 
The CCA ‑IMT was assessed by ultrasound (B pre‑
sentation, Acuson Siemens 128 XP/10 apparatus 
equipped with linear head at 5/7 MHz, Moun‑
tain View, California, United States). The mea‑
surements were performed bilaterally at 0.5 cm 
and 2 cm below the division of the common ca‑
rotid artery during diastolic phase of the heart 
cycle. The results were expressed as the arith‑
metic means of the values obtained for the left 
and right arteries.
Data on mortality were collected over a 5 ‑year 
period. CV mortality was defined as death due to 
myocardial infarction (MI), stroke, or heart fail‑
ure (HF). The date and cause of death was deter‑
mined on the basis of the patients’ hospital re‑
cords. The person who collected the data on mor‑
tality was blinded to the results of laboratory 
tests, histological examination, and CCA ‑IMT 
assessment.
The study was approved by the Bioethics Com‑
mittee of Jagiellonian University, and all patients 
signed an informed consent to participate in 
the study.
Laboratory tests In all patients, selected bio‑
chemical parameters were measured, including 
serum concentrations of creatinine, glucose, in‑
tact parathyroid hormone, total calcium and phos‑
phate, high ‑sensitivity CRP (hs ‑CRP), interleu‑
kin 6 (IL ‑6), PTX3, tumor necrosis factor recep‑
tor 2 (TNFR2), transforming growth factor β1 
(TGF ‑β1), hepatocyte growth factor (HGF), throm‑
bomodulin (TM), stromal cell ‑derived factor 1α 
(SDF ‑1α), osteoprotegerin (OPG), osteopontin 
(OPN), osteocalcin (OC), fibroblast growth fac‑
tor 23 (FGF ‑23), and fetuin A. The estimated GFR 
(eGFR) was calculated by the Modification of Diet 
in Renal Disease formula: eGFR = 186 × serum 
creatinine (μmol/l) × 0.0113–1.154 × age–0.203 × 11
4 × (0.742 for women).14
Blood samples were obtained at baseline, on 
the morning before creation of AVF for HD ac‑
cess. Serum samples for enzyme ‑linked immu‑
nosorbent assays (ELISAs) were aliquoted and 
stored at –70ºC until assayed (no longer than 3 
months). Plasma samples used to assess oxida‑
tive stress parameters were protected from light, 
placed on ice, and centrifuged within 2 hours af‑
ter collection, then aliquoted and stored at –30ºC 
until analysis (no longer than 1 month).
Routine biochemical tests were carried out us‑
ing automatic biochemical analyzers: Hitachi 917 
(Hitachi, Japan) and Modular P (Roche Diagnos‑
tics, Mannheim, Germany). The concentration of 
hs ‑CRP was measured using the immunonephe‑
lometric method (Nephelometer BN II, Siemens 
Healthcare Diagnostics, Germany).
atherosclerotic lesion development, apoptotic 
cell clearance, tissue repair, and regulation of re‑
nal immunopathology.4
PTX3 is a secreted glycoprotein belonging to 
the pentraxin family. The molecule is so called 
long pentraxin, structurally related to, but distinct 
from, classic short pentraxins, such as C ‑reactive 
protein (CRP) and serum amyloid P. However, un‑
like CRP, which is synthesized mainly in the liver, 
PTX3 is synthesized at the site of inflammation.
PTX3 ‑positive neutrophils infiltrate atheroscle‑
rotic plaques, suggesting that PTX3 derived from 
neutrophils (and also from macrophages) plays 
an important role in atherogenesis.5
Elevated systemic PTX3 levels appear to be 
a powerful marker of inflammatory status, bet‑
ter than CRP, and a superior outcome predictor in 
patients with CKD.6-8 Sjoberg et al9 reported that 
PTX3 is a rapid and sensitive marker of inflamma‑
tion in patients with CKD, and higher PTX3 levels 
are associated with lower glomerular filtration rate 
(GFR) and independently predict incident CKD in 
elderly patients. Zhou et al10 postulated that this 
marker could be a better predictor of peripheral 
artery disease than CRP in patients on hemodial‑
ysis (HD). Blood vessels produce large amounts of 
PTX3 during inflammation, and the level of circu‑
lating PTX3 increases in several pathological con‑
ditions affecting the CV system.5 The presence of 
aortic valve calcifications was independently asso‑
ciated with PTX3 levels, in addition to age, CKD, 
and coronary artery calcifications. Interestingly, 
PTX3 levels and age were independent predictors 
of the presence of aortic valve calcifications in pa‑
tients without aortic valve stenosis.11
The aim of the present study was to assess 
the relationship between serum PTX3 levels and 
all ‑cause and CV mortality in patients with CKD 
during a 5 ‑year follow ‑up. Additionally, we stud‑
ied the associations between serum concentra‑
tion of PTX3 and selected markers of inflamma‑
tion, oxidative stress, endothelial dysfunction, 
and bone turnover, as well as radial artery calci‑
fication assessed histologically and common ca‑
rotid artery intima–media thickness (CCA ‑IMT) 
measured by ultrasound.
PATIENTS AND METHODS Study design The study 
included patients with stage 5 CKD in whom ar‑
teriovenous fistula (AVF) for HD access was cre‑
ated for the first time, allowing collection of radi‑
al artery samples for a histological examination. 
Cross ‑sectional data were obtained immediate‑
ly before the procedure and included clinical as‑
sessment of patients, CCA ‑IMT measurements, 
and assessment of laboratory parameters (mark‑
ers of inflammation, oxidative stress, endotheli‑
al dysfunction, and bone turnover). Then the pa‑
tients were prospectively followed for 5 years, 
and the data on both all ‑cause and CV mortali‑
ty were collected.
Patients The study population consisted of 78 
consecutive patients (stage 5 CKD) treated at the 
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proportional hazard models included PTX3 (as 
continuous variable) and a priori selected vari‑
ables that have been associated with survival 
in CKD, as well as the main confounders (age 
and dialysis status at baseline). All tests were 
2 ‑tailed and the results were considered signif‑
icant at a P value of 0.05 or less. The analysis 
was performed with the use of Statistica 10 soft‑
ware (StatSoft, Tulsa, Oklahoma, United States).
RESULTS Associations between PTX3 concentra-
tions and the markers of inflammation, endothelial 
dysfunction, and oxidative stress Median serum 
PTX3 concentrations in the studied group of 78 
patients with stage 5 CKD were 1.43 ng/ml (0.74; 
2.50 ng/ml). Patients with PTX3 levels above 
the median had lower body mass index (BMI). 
They were more often on dialysis at baseline, and 
among those dialyzed, the treatment duration 
was longer (TABLE 1). As expected, patients with 
higher PTX3 were characterized by higher con‑
centrations of other inflammatory markers: fi‑
brinogen, hs ‑CRP, IL ‑6, TNFR2, TGF ‑β1, and 
HGF, and lower albumin concentrations. More‑
over, they had higher OPN, OPG, FGF ‑23, TM, 
and SDF ‑1α levels as well as lower uric acid lev‑
els (TABLE 1).
PTX3 concentrations significantly correlat‑
ed with age, BMI, dialysis treatment duration 
at baseline, serum creatinine and uric acid lev‑
els, other studied inflammatory markers, mark‑
ers of mineral and bone metabolism, and mark‑
ers of endothelial cell damage (TABLE 2). In mul‑
tiple regression, log(OPG) significantly predict‑
ed log(PTX3) (beta [standard error]: 0.39 [0.14]; 
P = 0.039) independently of age, dialysis status 
at baseline, log(IL ‑6), and log(TM).
Histological examination of the radial artery Miner‑
alization of the arterial wall was identified in his‑
tological sections stained with alizarin red. Calci‑
fications of various grades (FIGURE 1) were detect‑
ed in radial artery samples of 30 patients (56%). 
The mineral deposits were found almost exclu‑
sively in the vascular media.
Median serum PTX3 concentrations did not sig‑
nificantly differ between patients with and with‑
out radial artery calcifications: 1.39 ng/ml (0.74; 
2.93 ng/ml) and 1.02 ng/ml (0.56; 2.27 ng/ml), 
respectively, P = 0.2. There was no significant as‑
sociation between PTX3 levels and progression 
of calcifications.
Common carotid artery ultrasound Data from com‑
mon carotid artery ultrasound were available in 51 
patients (65%), including 33 men and 21 women 
(mean [SD] age, 62 [17] years), of whom 31 (57%) 
were on HD at baseline. CCA ‑IMT values were not 
associated with PTX3 concentrations (r = 0.22; P 
= 0.1). Also, median PTX3 levels did not differ be‑
tween patients with and without atherosclerotic 
plaques in the common carotid artery: 1.85 ng/ml 
(0.78; 0.79) and 1.04 ng/ml (0.59; 1.99), respec‑
tively, P = 0.1.
Inflammatory, calcification, and endothelial 
dysfunction markers were assessed using ELISA 
microplate immunoassays and ELX808 automat‑
ic reader (BIO ‑TEK® Instruments Inc., Vermont, 
Vermont, United States). The following kits were 
applied: IL ‑6, PTX3, TNFR2, TGF ‑β1, HGF, TM, 
SDF ‑1α (R&D Systems, Minneapolis, Minnesota, 
United States); OPG, fetuin A (BioVendor, Brno, 
Czech Republic); OPN (R&D Systems); OC (Me‑
tra/Quidel, San Diego California, United States); 
and FGF ‑23 (Immunotopics Int., San Clemente, 
California, United States).
Histology In 45 patients (27 men and 18 women; 
mean [SD] age, 62 [16] years; 25 patients on HD 
at baseline), samples of peripheral arteries were 
collected for histological assessment. Small frag‑
ments of the radial artery wall (approx. 5 × 2 mm 
in size) were excised during the first creation of 
AVF for HD access and fixed overnight in 10% 
phosphate ‑buffered formalin. Serial 10 μm ‑thick 
cryosections were cut and thaw ‑mounted on poly‑
‑L‑lysine coated slides. Sections were stained with 
alizarin red and were examined under an Olympus 
BX ‑50 microscope (Olympus, Tokyo, Japan). Dig‑
ital images were acquired using Olympus DP ‑71 
digital CCD camera controlled by the Olympus 
AnalySIS FIVE software. The extent of calcifica‑
tion was semiquantitatively evaluated by 2 inde‑
pendent observers. The degree of mineralization 
was classified according to the following scale: 0, 
no mineral content; 1, a few small dispersed con‑
cretions; 2, numerous small dispersed concre‑
tions; 3, larger granular concretions; and 4, large 
areas occupied by fused mineral deposits.
The reproducibility of the morphological anal‑
ysis was confirmed by the Bland –Altman meth‑
od and by calculating intraclass correlation coef‑
ficient (which was 0.88).
Statistical analysis The number of patients (per‑
centage of the group) were reported for catego‑
ries. Data were expressed as mean (SD) or me‑
dian (Q1; Q3) for continuous variables, depend‑
ing on the distribution (assessed by the Shap‑
iro–Wilk test). The χ2 test was used for contin‑
gency tables. The t test or Mann–Whitney test 
was employed for simple comparisons between 
the groups. Simple correlations were assessed 
using the Pearson correlation coefficient, after 
log ‑transformation of right ‑skewed variables. 
A multiple linear regression analysis was used 
to find independent predictors of log(PTX3). 
The analysis included the main confounders (age 
and dialysis status at baseline) and the most rep‑
resentative predictors chosen for each group, 
that is, the  markers of inflammation, bone 
and mineral metabolism, and endothelial dys‑
function. Survival time was calculated between 
the start date at the inclusion of a patient into 
the study and the date at death, renal transplan‑
tation, or the end of the study. It was estimated 
using the Kaplan–Meier method and compared 
with the log ‑rank test. Simple and multiple Cox 
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months (23; 56 months), and the median survival 
time was not reached (Q1: 25 months). All ‑cause 
and CV mortality was higher in the group of pa‑
tients with serum PTX3 concentrations above 
the median value (18 vs 9 deaths; 17 vs 8 deaths 
from CV causes; FIGURE 2); the hazard ratio for 
death was 2.13 (95% CI, 1.01–4.49; P = 0.048) in 
patients with PTX3 levels above the median value 
as compared with those with PTX3 levels below 
Association between pentraxin 3 and mortality Dur‑
ing the 5 ‑year follow ‑up, 27 patients (35%) died, 
of whom 25 died due to CV causes. The causes of 
death were as follows: HF in 11 patients, MI in 11, 
stroke in 3, and neoplasm in 2. During the follow‑
‑up, all patients who had not been dialyzed 
at baseline began HD therapy and 14 patients 
(18%) underwent renal transplantation. The me‑
dian follow ‑up time in the studied group was 48 
TABLE 1 Clinical characteristics and laboratory data of patients with pentraxin 3 concentrations below and above 
the median value of 1.43 ng/ml
Parameter PTX3 ≤1.43 ng/ml  
(n = 39)
PTX3 >1.43 ng/ml 
(n = 39)
P value
Age, y, mean (SD) 59 (16) 64 (17) NS
Male sex, n (%) 23 (60) 23 (59) NS
Hemodialyzed, n (%) 20 (51) 31 (79) 0.009
Dialysis therapy durationa, mo, median (Q1; Q3) 10 (3; 30) 28 (6; 60) 0.048
BMI, kg/m2, mean (SD) 27.2 (5.9) 24.6 (4.4) 0.024
Diabetes, n (%) 11 (28) 15 (38) NS
Hypertension, n (%) 33 (85) 36 (92) NS
Dyslipidemia, n (%) 21 (54) 20 (51) NS
SCORE, %, median (Q1; Q3) 4.0 (2.0; 9.0) 6.5 (3.0; 14.5) NS
CCA ‑IMTb, mm, mean (SD) 0.93 (0.13) 0.96 (0.16) NS
Atherosclerotic plaques in CCAb, n / N (%) 8 / 27 (30) 12 / 24 (50) NS
Radial artery calcificationsc, n / N (%) 16 / 25 (64) 13 / 20 (65) NS
Serum creatinine, μmol/l, median (Q1; Q3) 403 (314; 512) 452 (372; 596) NS
Uric acid, μmol/l, median (Q1; Q3) 395 (285; 460) 288 (228; 369) 0.002
Ca × Pi, mmol2/l2, median (Q1; Q3) 2.99 (2.75; 3.70) 3.57 (2.88; 4.16) NS
iPTH, pg/ml, median (Q1; Q3) 279 (172; 453) 208 (152; 655) NS
OPG, pmol/l, median (Q1; Q3) 5.93 (3.66; 8.05) 8.58 (6.21; 13.47) <0.001
OPN, ng/ml, median (Q1; Q3) 219 (160; 344) 356 (238; 631) 0.003
OC, ng/ml, median (Q1; Q3) 42.5 (29.8; 74.6) 44.1 (33.6; 70.0) NS
Fetuin A, g/l, mean (SD) 0.234 (0.041) 0.245 (0.066) NS
FGF ‑23, RU/ml, median (Q1; Q3) 522 (265; 1243) 2529 (1006; 5066) <0.001
Albumin, g/l, mean (SD) 42.0 (4.0) 39.1 (5.6) 0.035
Fibrinogen, g/l, median (Q1; Q3) 4.73 (4.34; 5.53) 5.50 (5.02; 5.96) 0.011
hs ‑CRP, mg/l, median (Q1; Q3) 3.08 (1.26; 8.47) 12.20 (6.68; 28.85) <0.001
IL ‑6, pg/ml, median (Q1; Q3) 2.60 (1.52; 5.61) 5.58 (3.63; 8.67) <0.001
IL ‑18, ng/ml, median (Q1; Q3) 607 (461; 775) 702 (505; 990) NS
TNFR2, µg/ml, median (Q1; Q3) 11.7 (9.3; 16.5) 16.6 (13.7; 23.4) <0.001
TGF ‑β1, µg/ml, median (Q1; Q3) 5.01 (3.46; 6.44) 5.83 (4.41; 8.00) 0.043
HGF, ng/ml, median (Q1; Q3) 1.95 (1.59; 2.53) 2.99 (2.43; 4.02) <0.001
TM, ng/ml, median (Q1; Q3) 15.8 (13.6; 19.2) 17.5 (14.9; 22.5) 0.035
SDF ‑1α, ng/ml, median (Q1; Q3) 2.94 (2.63; 3.37) 3.39 (2.83; 3.62) 0.024
a Data provided for patients dialyzed at baseline
b Data provided for patients with available results of common carotid artery ultrasound (ie, 27 patients with PTX3 
≤1.43 ng/ml and 24 with PTX3 >1.43 ng/ml)
c Data provided for patients with available results of radial artery alizarin ‑red staining (ie, 25 patients with PTX3 
≤1.43 ng/ml and 20 with PTX3 >1.43 ng/ml)
Abbreviations: BMI, body mass index; Ca, calcium; CCA ‑IMT, common carotid artery intima–media thickness; FGF ‑23, 
fibroblast growth factor 23; HGF, hepatocyte growth factor; hs ‑CRP, high ‑sensitivity C ‑reactive protein; IL ‑6, interleukin 
6; IL ‑18, interleukin 18; iPTH, intact parathyroid hormone; NS, nonsignificant, OC, osteocalcin; OPG, osteoprotegerin; 
OPN, osteopontin; Pi, phosphate; PTX3, pentraxin 3; SCORE, Systematic Coronary Risk Evaluation; TGF ‑β1, 
transforming growth factor β1; SDF‑1α, stromal cell ‑derived factor 1α; TM, thrombomodulin; TNFR2, tumor necrosis 
factor receptor 2
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FIGURE 1 Sections of 
radial arteries stained 
with alizarin red, 
demonstrating low degree 
of radial artery calcification 
(RAC) (A) and high 
degree of RAC (B).
the median value. In an unadjusted Cox regres‑
sion analysis, PTX3 concentrations significantly 
predicted all ‑cause and CV mortality (TABLE 3). This 
association was confirmed after adjustment for 
dialysis status at baseline and for other known 
predictors of mortality such as age, serum OPG 
and hs‑CRP concentrations, the presence of radi‑
al artery calcifications, and the value of CCA ‑IMT 
(TABLE 3). Of the other inflammatory markers, only 
hs ‑CRP was significantly associated with CV mor‑
tality: hazard ratio, 1.01 (95% CI, 1.002–1.03) 
(P = 0.047), while no such association was ob‑
served for IL ‑6 (P = 0.6), IL ‑18 (P = 0.9), TNFR2 
(P = 0.9), TGF ‑β (P = 0.4), and HGF (P = 0.085). 
However, only PTX3 levels significantly predict‑
ed CV mortality in addition to CV risk assessed 
using the SCORE (TABLE 4).
DISCUSSION To our knowledge, the relation‑
ship between PTX3 levels and long ‑term mor‑
tality, the presence of calcification in the media 
of the radial artery, as well as CCA ‑IMT in pa‑
tients with CKD has not been studied before. Our 
study showed that increased PTX3 concentrations 
A B
FIGURE 2  
Cardiovascular mortality 
among patients with 
pentraxin 3 (PTX3) above 
(blue line) and below 
(black line) the median 
value of 1.43 ng/ml. The 
lower quartile of survival 
time was 24 months in 
the group of patients 
with PTX3 above 
the median (median 
survival not reached) and 
was not reached in 
the group with PTX3 
below the median value.
Follow-up, mo
40
20
0
0 12
PTX3 ≤1.43 ng/ml: median survival not reached
PTX3 >1.43 ng/ml: median survival, 54 months
24 36 48 60
60
80
P = 0.047
100
Cu
m
ul
at
iv
e 
su
rv
iv
al
, %
TABLE 2 Simple correlations between log(PTX3) and other studied variables
Variable r P value
Age 0.25 0.028
Log(BMI) –0.25 0.024
Dialysis treatment duration 0.37 0.001
Log(serum creatinine) 0.23 0.039
Log(hs ‑CRP) 0.42 <0.001
Log(IL ‑6) 0.46 0.001
Log(IL ‑18) 0.30 0.007
Log(TNFR2) 0.44 <0.001
Log(TGF ‑β1) 0.31 0.006
Log(HGF) 0.49 <0.001
Log(Ca × Pi) 0.25 0.030
Log(OPG) 0.51 <0.001
Log(OPN) 0.31 0.006
Log(FGF ‑23) 0.46 <0.001
Log(TM) 0.26 0.025
SDF ‑1α 0.29 0.012
Uric acid –0.35 0.002
Abbreviations: see TABLE 1
RAC 1° RAC 4°
100 µm 200 µm
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associated with a higher risk of all ‑cause mortality 
(759 events, 28.3%), CV mortality (587 patients, 
21.9%), or hospitalization for worsening HF (720 
events, 26.9%). Three ‑month changes in PTX3 lev‑
els were associated with fatal events after adjust‑
ment for hs ‑CRP or N ‑terminal pro ‑B‑type natri‑
uretic peptide. It is worth noting that in 2 inde‑
pendent randomized clinical trials including pa‑
tients with CHF, elevated PTX3 levels were con‑
sistently associated with fatal outcomes. Patients 
with acute coronary syndrome also showed high 
levels of PTX3. Mielva et al20 recruited 873 pa‑
tients presenting with chest pain for a prospec‑
tive observational study. During a 7 ‑year follow‑
‑up, 332 patients died and 203 suffered from tro‑
ponin T ‑positive nonfatal cardiac event. In a mul‑
tivariate analysis, PTX3 levels above the medi‑
an value of 5.88 ng/ml ndependently predicted 
mortality. Similarly, in our study all ‑cause mor‑
tality was higher in the group of patients with se‑
rum PTX3 concentrations above the median val‑
ue. The risk of death at 5 years in these patients 
was more than twice as high as that for patients 
with PTX3 levels below the median value. In pa‑
tients with PTX3 above 1.43 ng/ml, the median 
survival was 54 months. The baseline PTX3 con‑
centration predicted mortality not only in an un‑
adjusted analysis, but also in the models adjust‑
ed for important predictors of death. 
significantly predicted both all ‑cause and CV mor‑
tality in patients with advanced CKD. So far, Su‑
liman et al15 and Sjoberg et al16 demonstrated 
that high PTX3 levels in HD patients were in‑
dependently associated with all ‑cause mortality. 
PTX3 has been shown to be a strong predictor of 
CV events in advanced CHF. Liu et al17 revealed 
that plasma PTX3 levels were significantly high‑
er in patients with CHF than in healthy individu‑
als. Interestingly, PTX3 levels increased with ad‑
vancing class in the New York Heart Association 
(NYHA) functional classification and could pre‑
dict future cardiac events in patients with CHF. 
Moreover, in a multivariate Cox regression anal‑
ysis, which included well ‑known clinical and bio‑
chemical risk factors for CHF, the plasma levels of 
PTX3 remained an independent predictor of car‑
diac events in those patients. In another study, 
Suzuki et al18 found that PTX3 levels increased 
significantly in patients with CHF as compared 
to healthy controls and also increased with ad‑
vancing NYHA functional class. These authors 
also demonstrated that the plasma PTX3 level 
could be a prognostic risk factor in patients with 
CHF. Similarly, the Controlled Rosuvastatin Mul‑
tinational Trial in CHF (CORONA, N = 1457 pa‑
tients) and GISSI ‑Heart Failure trials (N = 1233)19 
assessed the correlation between plasma levels 
of PTX3 and mortality in CHF patients during 
a 3 ‑month follow ‑up. Elevated PTX3 levels were 
TABLE 3 Cox regression models for all ‑cause and cardiovascular mortality. 
Independent 
variable
All ‑cause mortality Cardiovascular mortality
Simple model Multiple model 1a Multiple model 2a,b Simple model Multiple model 1a Multiple model 2a
PTX3, per 1 ng/ml 1.28 (1.12–1.48); 
P <0.001
1.31 (1.06–1.64); 
P = 0.013
1.28 (1.05–1.55); 
P = 0.012
1.28 (1.11–1.47); 
P <0.001
1.33 (1.07–1.66); 
P = 0.010
1.28 (1.04–1.57); 
P = 0.017
OPG, per 1 pmol/l – 1.07 (0.97–1.19); 
P = 0.2
– – 1.05 (0.94–1.17); 
P = 0.3
–
hs ‑CRP, per 1 mg/l – 1.01 (0.99–1.02); 
P = 0.3
– – 1.01 (0.99–1.02); 
P = 0.5
–
Radial artery 
calcifications
– – 1.35 (0.36–5.06); 
P = 0.6
– – 1.75 (0.40–7.62); 
P = 0.4
CCA ‑IMT, per 
0.1 mm
– – 0.99 (0.57–1.64); 
P = 0.9
– – 1.10 (0.66–1.86); 
P = 0.7
Data are reported as hazard ratio (95% CI) and P value. 
 
a Multiple models 1 and 2 are adjusted for age and dialysis status at baseline.
b Multiple model 2 was calculated for patients who underwent histological examination of the radial artery and ultrasonography of the common 
carotid artery (n = 45).
Abbreviations: see TABLE 1
TABLE 4 Comparison of high ‑sensitivity C ‑reactive protein and pentraxin 3 as predictors of cardiovascular mortality 
in addition to classic cardiovascular risk factors as assessed using SCORE
Independent variable Model 1 Model 2
SCORE, per 1% 1.06 (1.01–1.12); P = 0.016 1.07 (1.02–1.13); P = 0.006
PTX3, per 1 ng/ml 1.18 (1.02–1.37); P = 0.026 –
hs ‑CRP, per 1 mg/l – 1.01 (0.99–1.02); P = 0.3
Data are reported as hazard ratio (95% CI) and P value.
Abbreviations: see TABLE 1
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These studies, however, demonstrated an associ‑
ation of high PTX3 levels with late CV complica‑
tions of atherosclerosis such as angina, periph‑
eral artery disease, MI, and stroke.
In agreement with previous studies,19,21 our 
patients with higher PTX3 levels were older and 
had lower BMI. Bosutti et al26 reported an inverse 
association of PTX3 with fat mass and hypoth‑
esized that nutrition can play a role in the regu‑
lation of PTX3 levels. Similarly, in the study of 
Sjoberg et al,16 patients with high stable PTX3 
levels had significantly lower albumin levels and 
BMI, lean BMI, and fat BMI, as well as higher Da‑
vies score27 as compared to those with stable low 
PTX3 levels, indicating that patients with elevat‑
ed PTX3 levels suffered from protein ‑energy wast‑
ing and had more comorbidities. A possible expla‑
nation for this is advanced state of inflammation, 
being a part of the malnutrition ‑inflammation‑
‑atherosclerosis syndrome in patients with CKD, 
which decreases the BMI.
In our study, in line with other reports,28,29 pa‑
tients with higher concentrations of PTX3 had 
more advanced renal failure and more severe in‑
flammation and endothelial dysfunction. Tong 
et al28 showed that patients (stage 3–5 CKD) with 
protein ‑energy wasting, inflammation, and CV 
disease had higher concentrations of PTX3 than 
their healthy counterparts. Moreover, patients 
with high PTX3 levels had higher all ‑cause but 
not CV mortality. Similarly to the results report‑
ed by Suliman et al,15 in our study the PTX3 con‑
centration was positively correlated with hs ‑CRP 
and IL ‑6 levels, and negatively with serum albu‑
min levels. Release of proinflammatory cytokines 
and metabolic abnormalities associated with sys‑
temic inflammation belong to principal mecha‑
nisms leading to endothelial dysfunction in pa‑
tients with uremia. Local ischemia damages en‑
dothelial cells and stimulates production of long 
PTX in the vasculature, and PTX3 is rapidly de‑
tectable in the systemic circulation.1,3,4
We demonstrated a significant correlation of 
PTX3 concentrations with TM and SDF ‑1α, bio‑
chemical markers of endothelial activation, which 
leads to changes in the vessel wall. Vascular calci‑
fications in patients with uremia are located both 
in the intima and in the media.30,31 In the pres‑
ent study, an interesting finding is the correla‑
tion between PTX3 levels and markers of calci‑
fication: OPG, OPN, and FGF ‑23. Furthermore, 
elevated OPG levels predicted high PTX3 levels 
independently of age, time on dialysis, inflam‑
mation, and endothelial damage. PTX3 concentra‑
tions significantly correlated not only with OPG 
but also with TNFR2. According to our previous 
reports,31,32 OPG may be an indicator of inflam‑
mation, atherosclerosis, and medial artery calci‑
fication. OPG may also participate in the calcific 
degeneration of the heart valves.33
This study has demonstrated that increased 
PTX3 concentrations significantly predict CV mor‑
tality in patients with advanced CKD regardless 
of serum OPG and hs ‑CRP levels, the presence of 
In the Multi ‑Ethnic Study of Atherosclerosis 
(MESA),21 PTX3 was not associated with the risk 
of stroke, CV death, or non ‑CV death but it was 
related to increased risk of MI, CVD, and CHF 
events. The authors showed that in a population‑
‑based study of men and women from 4 ethnic 
groups (2880 participants with a follow ‑up of 
8.5 years) who were free of clinical CVD these 
associations were independent of hs ‑CRP levels. 
On the other hand, in the early Cardiovascular 
Health Study,2 conducted by the same authors 
in the group of over 1500 participants, PTX3 lev‑
els were significantly associated with the risk of 
CV and all ‑cause death. In that study, PTX3 lev‑
els were not associated either with incidents of 
angina, MI, or stroke or with a combined end‑
point of angina, MI, stroke, and CV death. Simi‑
larly to the MESA study, the addition of hs ‑CRP 
to the model had no significant effect on risk pre‑
diction by PTX3, although of all other inflamma‑
tory markers studied only hs ‑CRP was signifi‑
cantly associated with CV mortality. However, 
only PTX3 significantly predicted CV mortality 
in addition to CV risk assessed using the SCORE. 
Likewise, there was no significant interaction be‑
tween PTX3 and hs ‑CRP levels for any outcome. 
This might confirm our assumption that PTX3 re‑
flects different aspects of atherosclerosis ‑related 
inflammation than hs ‑CRP and may provide ad‑
ditional insight into the development of vascular 
damage in patients with CKD. It is also consistent 
with our hypothesis that baseline PTX3 concen‑
trations as an indicator of local vascular damage 
response levels could provide more valuable in‑
formation on the development and progression 
of atherosclerosis than nonspecific markers such 
as hs ‑CRP. PTX3 thus appears to be a more spe‑
cific marker for local vascular inflammation but 
not for systemic inflammation.
So far, the PTX3 concentration has been pro‑
posed to be a risk marker for coronary artery 
disease,22 MI,23 and aortic valve calcification.11 
The study of Hudzik et al24 showed that the PTX3 
level was a marker of advanced coronary artery 
disease. Similarly as in our study, PTX3 levels 
were correlated with other CV risk factors such 
as hs ‑CRP. Moreover, in our study PTX3 appeared 
to be a marker of the risk of CV death (related to 
HF, MI, or stroke) in patients with CKD. The PTX3 
level was independently associated with CV mor‑
tality, but there was no association with elevat‑
ed CCA ‑IMT, an early precursor of atherosclero‑
sis, and there was no relationship with severity 
of calcifications in the media of the radial artery. 
This could be due to a relatively small number 
of patients from whom these data were avail‑
able. However, the results of our study are con‑
sistent with those reported by Knoflach et al25 for 
the Atherosclerosis Risk Factors in Male Young‑
sters (ARMY) and the Atherosclerosis Risk Factor 
in Female Youngsters (ARFY) studies, where no 
relationship was found between the intima–me‑
dia ratio of large arteries (CCA ‑IMT and femoral 
artery IMT) and elevated concentrations of PTX3. 
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radial artery calcifications, the value of CCA ‑IMT, 
age, and dialysis status at baseline. On the ba‑
sis of the earlier reports and the present results, 
it appears that the baseline measurement of se‑
rum PTX3 levels should be considered as a rou‑
tine, noninvasive tool in the evaluation of CV 
risk at the initiation of renal replacement thera‑
py. The pathogenetic role of PTX3 in CVD remains 
unclear and requires further research. Howev‑
er, although limited by a relatively low number 
of patients, our study suggests that PTX3 might 
be a useful marker of risk for cardiorenal syn‑
drome and that assessment of PTX3 concentra‑
tions could substantially improve the risk strati‑
fication of patients with advanced CKD.
In conclusion, we postulate that PTX3 might 
be an early biomarker of CV mortality in patients 
with advanced CKD, yet before the increase in 
the levels of a specific marker for systemic in‑
flammation such as hs ‑CRP. The prognostic val‑
ue of the initial measurement of PTX3 concen‑
trations for assessing CV risk in CKD could con‑
tribute to early prevention and reduction of mor‑
tality in this population.
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